CAMBRIDGE, Mass. and SEOUL, South Korea, Jan. 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Samsung today announced a collaboration aimed at fostering cutting-edge biopharmaceutical innovation poised to transform the world of healthcare through groundbreaking advancements in translational science and medicine..

马萨诸塞州剑桥市和韩国首尔，2024年1月8日/PRNewswire/--旗舰先驱，生物平台创新公司和三星今天宣布了一项合作，旨在通过转化科学和医学的突破性进展促进尖端生物制药创新，以改变医疗保健世界。。

Through this collaboration, Samsung will work alongside Flagship-founded companies, leveraging Samsung's leading technologies and capabilities to accelerate first and best-in-class therapies. The newly formed strategic partnership is an expansion of the ongoing cooperation between Samsung and Flagship.

通过这次合作，三星将与旗舰公司合作，利用三星领先的技术和能力来加速一流和一流的治疗。新成立的战略合作伙伴关系是三星与旗舰公司正在进行的合作的扩展。

The collaboration between Samsung and Flagship leverages the expertise of both organizations in the areas of life science technology, artificial intelligence, and CDMO services, and extends across Flagship's ecosystem of companies..

三星和旗舰公司之间的合作利用了两家公司在生命科学技术、人工智能和CDMO服务领域的专业知识，并扩展到了旗舰公司的生态系统。。

Key Highlights of the Collaboration:

合作的主要亮点：

Revolutionary Technology: The collaboration will leverage state-of-the-art technology including artificial intelligence, translational medicine, access to high quality clinical samples and Samsung's clinical trials infrastructure, and investment by Samsung in Flagship-founded companies.

革命性的技术：此次合作将利用最先进的技术，包括人工智能、转化医学、获取高质量临床样本和三星的临床试验基础设施，以及三星对旗舰公司的投资。

Shared Vision: Flagship Pioneering and Samsung share a common vision of transforming conventional drug discovery and development approaches to help bring new targeted therapeutic solutions to patients. The collaboration is driven by a commitment to pushing the boundaries of what is possible in the bio-pharmaceutical industry..

共同愿景：旗舰先锋和三星在改变传统药物发现和开发方法以帮助为患者带来新的靶向治疗解决方案方面有着共同的愿景。这种合作是由致力于突破生物制药行业可能的界限所推动的。。

'This collaboration represents a significant milestone in the pursuit of innovation and scientific excellence,' said Stephen Berenson, Managing Partner, Flagship Pioneering. 'As partners, we will bring together Flagship Pioneering's unparalleled expertise in inventing and developing revolutionary bioplatform companies with Samsung's strategic capabilities to reshape and empower the bio-pharmaceutical landscape, ultimately resulting in bigger leaps for patient care.'.

旗舰创业公司管理合伙人斯蒂芬·贝伦森（StephenBerenson）表示，此次合作是追求创新和科学卓越的一个重要里程碑作为合作伙伴，我们将把旗舰先锋在发明和发展革命性生物平台公司方面无与伦比的专业知识与三星重塑和授权生物制药领域的战略能力结合起来，最终为患者护理带来更大的飞跃。”。

'This newly formed collaboration is an important evolution of the ongoing relationship between two companies,' said Jaywoo Kim, executive vice president, Samsung C&T. 'We look forward to seeing the accelerating effect of Samsung's various technical expertise and extensive commercial capabilities on the future innovations Flagship and its ecosystem of companies will bring to market.'.

三星C&T执行副总裁杰武·金（JaywooKim）说，这种新形成的合作是两家公司之间持续关系的重要演变我们期待着看到三星的各种技术专长和广泛的商业能力对未来创新旗舰及其公司生态系统将带来的加速效应。”。

About Flagship Pioneering:

关于旗舰先锋：

Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $70 billion in aggregate value.

旗舰先锋是一家发明和建立平台公司的生物技术公司，每个公司都有潜力开发多种产品，以改变人类健康或可持续发展。自2000年推出以来，Flagship已经发起并培育了100多家科学企业，总价值超过700亿美元。

To date, Flagship has deployed over $3.6 billion in capital toward the founding and growth of its pioneering companies alongside more than $27 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 40 companies, including Denali Therapeutics (NASDAQ: DNLI), Foghorn Therapeutics (NASDAQ: FHTX), Generate:Biomedicines, Inari, Indigo Agriculture, Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB) and Tessera Therapeutics..

迄今为止，Flagship已经部署了超过36亿美元的资本，用于开创性公司的成立和发展，以及其他机构超过270亿美元的后续投资。目前的旗舰生态系统由40家公司组成，其中包括 Denali疗法 （纳斯达克：DNLI）， 雾角疗法 （纳斯达克：FHTX），生成：生物医学， 伊纳里， 靛蓝农业， 摩德纳 （纳斯达克：MRNA）， 欧米茄疗法 （纳斯达克：OMGA）， 萨那生物技术 （纳斯达克：萨那）， Seres治疗学 （纳斯达克：MCRB）和 Tessera Therapeutics。。

About Samsung C&T:

关于三星C&T：

Samsung C&T Corporation, a dynamic player in industries ranging from construction, trading, fashion and resorts, is actively expanding its portfolio with strategic investments in the biopharmaceutical industry. Since its investing in Samsung Biologics and Bioepis, Samsung Biologics' CDMO production capacity has grown to over 600 kilo liters and contribute greatly to the stabilization of the biopharmaceutical supply chain.

三星C&T公司是建筑、贸易、时尚和度假村等行业的活跃参与者，正在积极扩大其在生物制药行业的战略投资组合。自投资三星生物制品和Bioepis以来，三星生物制品的CDMO生产能力已增长至600千升以上，为稳定生物制药供应链做出了巨大贡献。

In addition, Samsung Bioepis has improved the accessibility of many patients around the world by successfully launching seven biosimilar products. Samsung C&T will continue investment in innovative technologies and businesses that contribute to 'improving quality of life' in various areas of bio & healthcare..

此外，三星Bioepis通过成功推出七种生物仿制药产品，改善了世界各地许多患者的可及性。三星C＆T将继续投资于创新技术和业务，这些技术和业务有助于在生物和医疗保健的各个领域“提高生活质量”。。

*Note: Samsung C&T, Samsung Biologics, Samsung Bioepis and Samsung Venture Investment Corporation are collectively referred to herein as Samsung.

*注：三星C＆T、三星生物制品、三星生物制品和三星风险投资公司在本文中统称为三星。

Flagship Media Contact:

旗舰媒体联系人：

Olivia Offner

奥利维娅·奥夫纳

[email protected]

[受电子邮件保护]

Samsung Media Contact:

三星媒体联系人：

Youkang Bae

Young Bae

[email protected]

[受电子邮件保护]

SOURCE Flagship Pioneering

SOURCE旗舰先锋